These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36969230)

  • 1. Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension.
    Guo Y; Ma X; Nie Y; Kostallari E; Gao J
    Front Immunol; 2023; 14():1174562. PubMed ID: 36969230
    [No Abstract]   [Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension.
    Juneja P; Tripathi DM; Kaur S
    Am J Physiol Gastrointest Liver Physiol; 2022 May; 322(5):G473-G479. PubMed ID: 35195034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver surgery in cirrhosis and portal hypertension.
    Hackl C; Schlitt HJ; Renner P; Lang SA
    World J Gastroenterol; 2016 Mar; 22(9):2725-35. PubMed ID: 26973411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients.
    Ratti L; Pozzi M; Bosch J
    Dig Liver Dis; 2005 Nov; 37(11):886-93. PubMed ID: 16172033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
    J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease.
    Guixé-Muntet S; Zhu CP; Xie WF; Gracia-Sancho J
    Pharmacol Ther; 2020 Nov; 215():107626. PubMed ID: 32659305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis].
    Lee JS; Kim JH
    Korean J Hepatol; 2007 Sep; 13(3):309-19. PubMed ID: 17898548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver elastography for the diagnosis of portal hypertension in patients with liver cirrhosis.
    Şirli R; Sporea I; Bota S; Raţiu I
    Med Ultrason; 2012 Sep; 14(3):225-30. PubMed ID: 22957328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.
    Mookerjee RP; Mehta G; Balasubramaniyan V; Mohamed Fel Z; Davies N; Sharma V; Iwakiri Y; Jalan R
    J Hepatol; 2015 Feb; 62(2):325-31. PubMed ID: 25152204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liver cirrhosis and portal hypertension].
    TYGSTRUP N
    Manedsskr Prakt Laegegern; 1960 May; 38():189-97. PubMed ID: 13840085
    [No Abstract]   [Full Text] [Related]  

  • 14. Cystic fibrosis-cirrhosis, portal hypertension, and liver biopsy: Reply.
    Lewindon PJ; Ramm GA
    Hepatology; 2011 Mar; 53(3):1065-6. PubMed ID: 21374683
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis.
    Moreno-Merlo F; Wanless IR; Shimamatsu K; Sherman M; Greig P; Chiasson D
    Hepatology; 1997 Sep; 26(3):554-60. PubMed ID: 9303482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis.
    Sarin SK; Sethi KK; Nanda R
    Gut; 1987 Mar; 28(3):260-6. PubMed ID: 3570030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Physiopathology of portal hypertension in liver cirrhosis].
    Cervela LA
    Rev Esp Enferm Apar Dig; 1973 Jan; 39(2):223-38. PubMed ID: 4690385
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatic perfusion index in portal hypertension of cirrhotic and non-cirrhotic aetiologies.
    Shikare SV; Bashir K; Abraham P; Tilve GH
    Nucl Med Commun; 1996 Jun; 17(6):520-2. PubMed ID: 8822751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portal hypertension; a consequence of biliary cirrhosis.
    HODGE D
    Aust N Z J Surg; 1956 Aug; 26(1):20-4. PubMed ID: 13355808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.